Healthcare

Marvell shares jump after the chip maker beats analysts’ fourth-quarter earnings estimates and issues solid guidance.

Shares in Broadcom rise after the chip maker beats Wall Street’s earnings targets for its fiscal first quarter.

Software stocks have taken a beating lately, but Veeva looks well-placed to weather the market’s artificial intelligence fears.

Sites like TrumpRx and retailers like Costco can help. Here’s how else to make the most of your drug coverage and avoid overpaying.

The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.

The agency plans to suspend enrollment of beneficiaries into certain Medicare Advantage plans, Elevance says.

Solventum reported adjusted earnings per share of $1.57 from sales of $2 billion. Wall Street was looking for earnings per share of $1.49 from sales of $2 billion.

The market is shaky, software stocks have gone off a cliff, and semiconductor stocks are giving back some of their gain. It’s time to tweak your portfolio.

Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.

Advanced Micro Devices rallies after the chip maker unveils a multiyear deal to supply computing power to Meta Platforms.

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.

The Danish drugmaker released a promising update about a trial in China, but that didn’t end a rough run for shares.

Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.

Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.

Novo shares slump after the Danish drugmaker’s experimental obesity drug fails to beat Lilly’s treatment in an 84-week trial.

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

Hims & Hers Health will buy Eucalyptus, an Australian digital health company, in a deal valued at $1.15 billion.

Buying coverage through ACA marketplaces is now costlier. How to ease the sting.

Nvidia shares rise after Meta Platforms expands an existing partnership with the AI chip designer.

Paramount Skydance stock rises after Warner Bros. Discovery says it will restart deal talks with the company.

Masimo stock jumps as it agrees to be acquired by Danaher. The company is perhaps best known for its yearslong patent dispute with Apple.

Medtronic says it expects to take a $185 million hit from tariffs in the fiscal year.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

Applied Materials shares surged after the semiconductor-equipment maker beat analysts’ quarterly earnings estimates.